Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
arcticnovartis

  • Shareholders approved 28th consecutive dividend increase to CHF 3.50 (+6.1%) per share for 2024, representing a 3.5% yield¹
  • Shareholders elected Giovanni Caforio as new member and Chair of the Board of Directors as well as Elizabeth McNally as new member of the Board of Directors. Joerg Reinhardt, Charles L. Sawyers and William T. Winters did not stand for re-election
/by

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
arcticnovartis

  • Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presented
  • New analyses of 52-week data from Phase III REMIX pivotal trials of investigational remibrutinib, demonstrating impact in key clinical outcomes for patients with CSU also to be presented
  • Regulatory submissions for remibrutinib as a treatment for CSU on track for filing in 1H 2025
/by

Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)

Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
arcticnovartis

  • If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5
  • Phase III data demonstrated clinically meaningful 35.1% proteinuria reduction6; also, a stabilization of estimated glomerular filtration rate (eGFR) – a key measure of kidney function – was observed6-8
/by

Parental leave – A leadership opportunity

Parental leave – A leadership opportunity
metzgma4

/by

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
arcticnovartis

  • Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway
  • Abelacimab is currently in Phase 3 development, with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillation
  • Acquisition adds a late-stage asset and is aligned with Novartis strategic focus, strength and expertise in the cardiovascular therapeutic area
/by

Novartis setzt die starke Umsatzdynamik mit Margenerhöhungen fort und erreicht 2024 wichtige Meilensteine bei Innovationen

Novartis setzt die starke Umsatzdynamik mit Margenerhöhungen fort und erreicht 2024 wichtige Meilensteine bei Innovationen
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR

Geschäftsjahr

/by

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

Full year

/by

Novartis presentation at J.P. Morgan Healthcare Conference 2025

Novartis presentation at J.P. Morgan Healthcare Conference 2025
imberje1

/by

Novartis presentation at J.P. Morgan Healthcare Conference 2025

Novartis presentation at J.P. Morgan Healthcare Conference 2025
imberje1

/by

Novartis Entresto® US patent upheld by US Court of Appeals

Novartis Entresto® US patent upheld by US Court of Appeals
arcticnovartis

Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto® (sacubitril/valsartan) combination patent.

We will work to appropriately enforce the combination patent through its pediatric exclusivity period expiring in July 2025. We will also continue to defend and protect all our important intellectual property and regulatory rights relating to Entresto.

/by